Received 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003
|
|
- Nicholas Bradley
- 5 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2003) 51, DOI: /jac/dkg152 Advance Access publication 13 March 2003 AUC 0 t /MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model Sheryl A. Zelenitsky 1 3 *, Robert E. Ariano 1 3, Harris Iacovides 1, Siyao Sun 1 and Godfrey K. M. Harding 2,4,5 Faculties of 1 Pharmacy and 2 Medicine, University of Manitoba; 3 Pharmacy, 4 Infectious Diseases and 5 Microbiology Laboratory, St Boniface General Hospital, Winnipeg, MB, Canada Received 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003 Objective: To conduct a comprehensive pharmacodynamic analysis of moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro infection model. Methods: In dose escalation studies, single doses with peak concentrations equivalent to 1, 2, 4, 8, 16 and 32 MIC against two isolates of S. pneumoniae were studied over 24 h. Traditional pharmacodynamic indices, including peak concentration divided by MIC (peak/mic), time of concentration above MIC (T > MIC) and AUC 24 /MIC, were estimated for all regimens. As a continuous index of fluoroquinolone exposure, AUC 0 t /MIC was also calculated, as AUC from time 0 to 1, 2 and 6 h divided by MIC. Correlations between pharmacodynamic indices and antibacterial effects were examined using linear and non-linear methods. In validation experiments, the pharmacodynamic model was used to predict bacterial kill curves, produced by simulated clinical doses of moxifloxacin and levofloxacin against two other S. pneumoniae isolates. Results: Peak/MIC was most predictive of early bacterial kill, whereas T > MIC was significantly associated with final bacterial counts at 24 h. Antibacterial effects were bacteriostatic when T > MIC was 48% and bactericidal when values exceeded 55%. AUC 0 t /MIC was strongly associated with bacterial kill throughout the dosing interval. Bactericidal activity and bacterial eradication were associated with AUC 0 t /MICs of 28 and 135, respectively. AUC 0 t /MIC was also highly predictive of bacterial kill curves produced by simulated clinical doses of moxifloxacin and levofloxacin (precision 0.36 log 10 cfu/ml, bias 0.02 log 10 cfu/ml). Conclusion: This study demonstrated the novel application of AUC 0 t /MIC as a continuous index of antibiotic activity, and provided extensive characterization of fluoroquinolone pharmacodynamics against S. pneumoniae. Keywords: moxifloxacin, levofloxacin, pharmacodynamics, pneumococcus Introduction Pharmacodynamic (PD) research explores complex antibiotic, bacterial and host interactions with the aim of improving the treatment of infectious diseases. Unlike traditional microbiological tests (i.e. MICs, MBCs), in vitro pharmacodynamic models (IPDMs) characterize important relationships between antibiotic concentrations, bacterial susceptibilities and antibacterial responses. Concentration profiles in vivo of different antibiotic regimens can be studied against various isolates to produce wide ranges of PD indices, including peak concentration divided by MIC (peak/mic), time of concentration above MIC (T > MIC) and AUC 24 /MIC. PD models can be constructed to identify PD indices and thresholds associated with optimal antibacterial effect. The application of these principles to clinical trials can be used to determine... *Corresponding author. Tel: ; Fax: ; zelenits@ms.umanitoba.ca The British Society for Antimicrobial Chemotherapy
2 S. A. Zelenitsky et al. optimal dosing strategies for the treatment of infectious diseases. Increases in penicillin-resistant Streptococcus pneumoniae and fluoroquinolone use for respiratory tract infections have stimulated significant interest in fluoroquinolone PDs against Gram-positive bacteria. IPDMs have demonstrated the generally rapid and potent activities of simulated clinical doses of agents such as gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin and trovafloxacin against susceptible S. pneumoniae isolates More comprehensive PD characterizations have shown concentration-dependent antibiotic activity, and further characterized relationships between peak/mic or AUC 24 /MIC and microbiological response AUC/MIC in vitro has been primarily investigated as an index of final or overall measures of bacterial kill. Most often, it has been associated with bacterial kill at the end of dosing intervals, or with areas related to the bacterial kill curve, such as the area between the control growth and time kill curves (ABBC), the area above the curve (AAC) and the area under the time kill curve (AUBC). Innovative work by Firsov et al. 15 found that measures of response that do not consider effect duration (i.e. time at which response is achieved) resulted in different AUC/MIC relationships. The investigators overcame this issue by using a measure of intensity of antibiotic effect (IE), or the area between control growth and time kill curves from time zero to the time of maximal regrowth, even if the time was greater than the dosing interval. 16 Our goal was to conduct a comprehensive PD analysis based on dose escalations of moxifloxacin and levofloxacin against S. pneumoniae in an IPDM. In addition to traditional PD indices (i.e. peak/mic, T > MIC, AUC 24 /MIC), we were interested in the application of the latter as a continuous index of fluoroquinolone exposure, and the potential association between AUC 0 t /MIC during the dosing interval and bacterial kill at the relative times. Materials and methods Bacterial strains Four strains of S. pneumoniae, including an ATCC (49619) isolate and three clinical (81, 63, 26) isolates from blood, were used. MICs were determined using the broth microdilution method described by the NCCLS. 17 Isolates ATCC and 63 were penicillin sensitive (MICs 0.03, 0.03 mg/l), and isolates 81 and 26 were penicillin resistant (MICs 2, 2 mg/l). Moxifloxacin and levofloxacin MICs were and 1 mg/l for isolates ATCC and 81, and 0.25 and 0.5 mg/l for isolates 63 and 26. Isolates ATCC and 81 were used in dose escalation studies, whereas isolates 63 and 26 were used in validation experiments. Antibiotics and medium Moxifloxacin was supplied by Bayer Corporation (West Haven, CT, USA) and levofloxacin by Ortho-McNeil Pharmaceutical (Raritan, NJ, USA). Mueller Hinton broth (Difco Laboratories, Detroit, MI, USA) supplemented with calcium 25 mg/l and magnesium 12.5 mg/l, with 4% lysed horse blood (Quelab, QC, Canada) was used in all experiments (CSMHB 4%LHB). In vitro pharmacodynamic model A one-compartment IPDM was used to simulate S. pneumoniae bacteraemia in an immunocompromised host. Four central compartments consisting of 250 ml glass flasks were stirred with magnetic bars and maintained at 37 C in a heated water bath. A computerized pump (Masterflex, Cole-Parmer Instrument Company, Chicago, IL, USA) was used to program the flow of sterile CSMHB 4%LHB through the central compartments, and produce 11 and 7 h elimination half-lives for moxifloxacin and levofloxacin, respectively. 18 Flow rates were calibrated prior to experiments and were measured again at 6 and 24 h. Experiments were excluded if the variation exceeded 5% of the original flow rate. Bacterial suspensions were prepared with the inoculation of colonies from solid blood agar into 100 ml of broth. Suspensions were incubated for 4 h, adjusted to a 0.5 McFarland s standard density and injected into the central compartments to yield initial inocula of cfu/ml at time zero. Dose escalation studies were performed by injecting single bolus doses of moxifloxacin and levofloxacin, with peak concentrations equivalent to 1, 2, 4, 8, 16 and 32 MIC, against isolates ATCC and 81. Samples were collected at 0, 0.5, 1, 2, 6 and 24 h, serially diluted in normal saline at 4 C and aliquotted (10 and 100 µl) onto solid blood agar in duplicate. Plates were incubated for 24 h and then viable colonies between 10 and 100 per plate were counted. The lower limit of detection was cfu/ml. To identify potential antibiotic carry-over, concurrent samples underwent two cycles of washing to remove antibiotic. Washing was performed by centrifuging at 4000g for 10 min, decanting the supernatant and suspending the remaining pellet in broth to the initial volume. Colony counts from washed and unwashed samples were compared. All experiments were performed with a growth control and in triplicate on separate occasions. Pharmacodynamic analysis Initial inocula were standardized to cfu/ml, and bacterial kill curves were constructed using mean log 10 cfu/ml (for experiments performed in triplicate) versus time. Twentyfour bacterial kill curves were produced from dose escalation studies of six concentration profiles of moxifloxacin and 906
3 Fluoroquinolone exposure in an infection model levofloxacin against two isolates. Colony count variation at each time point within and among experiments performed in triplicate was <10%, and antibiotic carry-over effects were not observed. Bacterial kill was measured by subtracting bacterial counts at 1, 2, 6 and 24 h from initial inocula, with positive values indicating net kill and negative values representing net growth. Bactericidal activity was defined as bacterial kill >3 log 10 cfu/ml, and bacterial eradication was defined as bacterial counts below the limit of detection, or bacterial kill >4 log 10 cfu/ml. Using a one-compartment, linear pharmacokinetic model, PD indices were estimated for the six concentration profiles of moxifloxacin and levofloxacin against isolates ATCC and 81. Peak/MIC was calculated as the peak concentration divided by MIC, T > MIC was the percentage of time of concentration above MIC for the 24 h dosing interval, and AUC 24 /MIC was the area under the concentration time curve from 0 to 24 h divided by MIC. For moxifloxacin, peak/mics of 1, 2, 4, 8, 16 and 32 produced T > MICs of 0, 46%, 92%, 100%, 100% and 100%, and AUC 24 /MICs of 12, 25, 50, 99, 198 and 396, respectively. For levofloxacin, the same peak/ MICs produced T > MICs of 0, 29%, 58%, 88%, 100% and 100%, and AUC 24 /MICs of 9, 18, 37, 73,147 and 293. As a continuous index of antibiotic exposure, AUC 0 t /MIC was also calculated as AUC from 0 to 1, 2 and 6 h divided by MIC (Figure 1). AUC 0 t /MICs, including AUC 0 1 /MIC, AUC 0 2 / MIC, AUC 0 6 /MIC and AUC 0 24 /MIC, ranged from 0.97 to 396 for moxifloxacin and 0.95 to 293 for levofloxacin. Relationships between the PD indices and bacterial kill were analysed using linear and non-linear (e.g. sigmoidal E max ) methods where appropriate. Goodness of fit for non-linear models was assessed using root mean squares, residual plots and Akaike s Information Criteria. The PD model was validated using simulated clinical doses of moxifloxacin 400 mg once daily and levofloxacin 500 mg once daily against two different clinical isolates, 63 and 26. In the IPDM, unbound concentration profiles for moxifloxacin (peak 2.3 mg/l, trough 0.5 mg/l, AUC mg h/l) and levofloxacin (peak 4.2 mg/l, trough 0.4 mg/l, AUC mg h/l) in adults with normal renal function were simulated. 18 AUC 0 t /MIC at 1, 2, 6 and 24 h were estimated, and used to predict bacterial kill curve responses. Measures of precision (i.e. root mean square error) and bias (i.e. mean error) were used to assess predictive performance. Statistical computations were executed using SPSS for Windows, release 11 software (SPSS Inc.). Results Representative bacterial kill curves for the dose escalation studies of moxifloxacin and levofloxacin against isolate 81 are shown in Figure 2. Similar results were observed against Figure 1. AUC 0 t /MIC as a continuous index of antibiotic exposure and antibacterial response. The upper broken line is the bacterial kill curve, the continuous line is the antibiotic concentration profile and the lower broken line is the MIC. Figure 2. Representative bacterial kill curves for dose escalation studies of moxifloxacin (a) and levofloxacin (b) against S. pneumoniae isolate 81. Curves were produced by doses with peak concentrations equivalent to 1 (open squares), 2 (open triangles), 4 (open circles), 8 (filled triangles), 16 (filled squares) and 32 (filled circles) MIC. 907
4 S. A. Zelenitsky et al. Figure 3. PD model of peak/mic and bacterial kill (log 10 cfu/ml) at 1 h. Data represent moxifloxacin (circles) and levofloxacin (squares) against S. pneumoniae isolates ATCC and 81 (S = 1.5, K m = 9.3, r 2 = 0.95). Figure 4. PD model of T > MIC and bacterial kill (log 10 cfu/ml) at 24 h. Data represent moxifloxacin (circles) and levofloxacin (squares) against S. pneumoniae isolates ATCC and 81 (S = 20.8, K m = 51.4, r 2 = 0.99). isolate ATCC Concentration-dependent activity was observed for both antibiotics. There was little to no bacterial inhibition when initial peak concentrations were equivalent to the MIC, and limited kill followed by regrowth when peaks were 2 MIC. All other doses, however, were at least bactericidal with >3 log 10 cfu/ml of bacterial kill at 24 h. Although peak/mic was associated with bacterial kill at all times, the relationship was strongest at 1 (Figure 3), 2 and 6 h, but less descriptive at 24 h. Peak/MIC also demonstrated significant influence on the time to bactericidal effect. Based on the PD model, peak/mics of 17 are bactericidal at 2 h, peak/mics of 5 are bactericidal at 6 h and peak/mics of 3 are not bactericidal until 24 h. T > MIC showed a strong association with final bacterial kill at 24 h (Figure 4). The steep PD response curve predicts that T > MICs of 48% and 55% are bacteriostatic and bactericidal, respectively. Furthermore, T > MICs over 70% result in bacterial eradication at 24 h. AUC 0 t /MIC exhibited the strongest association with bacterial kill during (i.e. at 1, 2 and 6 h) and at the end of dosing intervals (i.e. at 24 h) until regrowth or eradication. Figure 5 shows the PD model, derived from 80 data points, which Figure 5. PD model of AUC 0 t /MIC and bacterial kill (log 10 cfu/ml) where data represent estimated AUC 0 t /MIC and measured bacterial kill at 1, 2, 6 and 24 h. Data represent moxifloxacin (circles) and levofloxacin (squares) against S. pneumoniae isolates ATCC and 81 (S = 1.8, K m = 16.5, r 2 = 0.95). Figure 6. Predicted (broken line) and observed (solid lines) bacterial kill curves produced by simulated clinical doses of moxifloxacin (a) and levofloxacin (b) against S. pneumoniae isolates 63 (squares) and 26 (circles). describes the relationship between AUC 0 t /MIC at 1, 2, 6 and 24 h and bacterial kill at the respective times (S = 1.8, K m = 16.5, r 2 = 0.95). The model predicts that AUC 0 t /MICs of 28 and 135 produce 3 and 4 log 10 cfu/ml of bacterial kill, respectively. Furthermore, AUC 0 t /MIC was highly predictive of bacterial kill curves produced by simulated clinical doses of moxifloxacin and levofloxacin against S. pneumoniae isolates 63 and 26 (root mean square error 0.36 log 10 cfu/ml, mean error 0.02 log 10 cfu/ml) (Figure 6). 908
5 Fluoroquinolone exposure in an infection model Discussion As the use of fluoroquinolones for respiratory tract infections increases, the application of PD principles to maximize efficacy and minimize resistance becomes more important. This study provided a comprehensive characterization of traditional (i.e. peak/mic, T > MIC, AUC 24 /MIC) and novel (i.e. AUC 0 t /MIC) PD indices. In vitro, 12,13 animal 19,20 and human 21 studies of fluoroquinolones against S. pneumoniae have established AUC/MIC as a reliable index of response. AUC/MIC in vitro has been primarily investigated as an index of final or overall measures of bacterial kill. Traditionally, AUC 24 /MIC has been associated with bacterial kill at 24 h, or areas related to the bacterial kill curves over the dosing intervals (e.g. ABBC, AAC, AUBC). In this study, AUC 0 t /MIC was used as a continuous index of fluoroquinolone exposure, which predicted bacterial kill throughout the dosing interval until eradication or regrowth. Since AUC 0 t /MIC incorporated time as an independent variable, it predicted not only the effect, but also the time at which the response was achieved. The PD model predicts bactericidal activity when AUC 0 t /MICs are 28, and bacterial eradication when values exceed 135. It could be that, based on different pharmacokinetic and potency profiles, fluoroquinolone A achieves an AUC/MIC of 28 at 2 h, whereas agent B reaches this value at 12 h. The PD model would then predict a bacterial kill of 3 log 10 cfu/ml at 2 h with agent A, but not until 12 h with agent B. Furthermore, if agent A achieves an AUC/MIC of 135 at 12 h and agent B fails to reach this value during the dosing interval, the model would predict bacterial eradication with agent A only at 12 h. The lower threshold (i.e. 28) in this study is similar to that from previous reports. Optimal antibacterial activity has been associated with AUC 24 /MICs > 30 50, 2 4,7,12 whereas suboptimal effects with resistance or regrowth have been observed with AUC 24 /MICs < ,12,14 There is some variability in thresholds for bacterial eradication, which may be due to study isolates, ranges of AUC/MICs or definitions of response. Whereas some reports found bacterial eradication with AUC 24 /MICs > 30, 10,12 other studies, such as this one, demonstrated higher thresholds for complete antibacterial responses. 13,14 In a study of simulated clinical doses of six fluoroquinolones against two laboratory-derived ciprofloxacin-resistant isolates of S. pneumoniae, Coyle et al. 14 determined that bacterial counts below detection at 24 h were associated with AUC 24 /MICs > 82. Another investigation, which tested three doses of gemifloxacin against five isolates of S. pneumoniae, found maximal AUBCs at 48 h when AUC/ MICs were between 300 and As previously discussed, AUC 0 t /MIC expands the application of these thresholds from associations with final or overall antibacterial response to a PD index, which predicts both the magnitude and time of a desired effect. In other words, AUC 0 t /MIC considers potential differences between agents that may both achieve an AUC/MIC of 30, but where one reaches it at 2 h and the other at 24 h. The clinical application of AUC 24 /MIC has been demonstrated, whereas the relevance of AUC 0 t /MIC remains to be seen. Although optimal fluoroquinolone AUC 24 /MICs of are suggested for Gram-negative pathogens, 22 lower thresholds have been found for S. pneumoniae infections. One study of pneumococcal pneumonia in mice found a significant AUC 24 /MIC threshold of >160, 23 whereas a second animal study reported optimal responses, with values of Ambrose et al. 21 also found a lower threshold based on the analysis of data from two Phase III trials of levofloxacin versus gatifloxacin for community-acquired pneumonia or acute bronchitis involving S. pneumoniae. The probability of microbiological response was 100% compared with 64% when unbound AUC 24 /MICs were above and below 33.7, respectively. Although lower thresholds appear effective, there are concerns that such targets may promote bacterial resistance. The characterization of antibiotic PDs is often complicated by the strong co-variance among indices. 18,24 In this study, peak/mic correlated well with early bacterial kill, but was less indicative of later bacterial counts at 24 h. Peak/MIC is founded on the concentration-dependent activity of fluoroquinolones, but does not consider antibiotic elimination and becomes less predictive of antibacterial response over time. On the other hand, AUC 0 t /MIC includes components of time and antibiotic elimination, and thereby maintains its predictive performance throughout the dosing interval. Finally, T > MIC is associated with fluoroquinolone activity, especially when concentrations fall below the MIC. 25 In contrast to peak/mic, T > MIC is most predictive of later bacterial counts at the end of dosing intervals. In this study, maximal antibacterial response at 24 h was associated with T > MICs > 70% (17 in 24 h). Although this threshold is similar to those of other IPDM studies, 7,13 it differs from another, in which bacterial eradication was observed when T > MICs exceeded 8 in 24 h (33%). 12 As mentioned previously, such variability may be explained by study isolates, ranges of T > MICs or definitions of response. This study has some important limitations. First, the PD characterizations were based on fluoroquinolone activity against two sensitive S. pneumoniae isolates. Dose escalations produced a wide range of values for most PD indices; however, data were less comprehensive for parameters such as T > MIC. In addition, AUC 0 t /MIC and the PD model would benefit from further validation using isolates with MICs outside the relatively narrow range of those used in this study. Although moxifloxacin and levofloxacin demonstrated the same PD responses, the study of other fluoroquinolones would also broaden the application. The lack of sample times between 6 and 24 h would not have added significantly to the 909
6 S. A. Zelenitsky et al. bacterial kill curves, but would have allowed validation at other times. Finally, the application of this PD model, in the setting of multiple dose regimens, requires further investigation. In conclusion, this study demonstrated the novel application of AUC 0 t /MIC as a continuous index of fluoroquinolone activity. It was predictive of bacterial kill until eradication or regrowth, and provided an extensive characterization of antibiotic PDs against S. pneumoniae. Acknowledgements This project was supported in part by Bayer Corporation. References 1. Bowker, K. E., Wootton, M., Rogers, C. A., Lewis, R., Holt, H. A. & MacGowan, A. P. (1999). Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. Journal of Antimicrobial Chemotherapy 44, Lacy, M. K., Lu, W., Xu, X., Tessier, P. R., Nicolau, D. P., Quintiliani, R. et al. (1999). Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrobial Agents and Chemotherapy 43, Lister, P. D. & Sanders, C. C. (1999). Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy 43, Lister, P. D. & Sanders, C. C. (1999). Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 43, MacGowan, A. P., Bowker, K. E., Wootton, M. & Holt, H. A. (1999). Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrobial Agents and Chemotherapy 43, Esposito, S., Noviello, S. & Ianniello, F. (2000). Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model. Journal of Chemotherapy 12, Hershberger, E. & Rybak, M. J. (2000). Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrobial Agents and Chemotherapy 44, Madaras-Kelly, K. J. & Demasters, T. A. (2000). In vitro characterization of fluoroquinolone concentration/mic antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease 37, Zinner, S. H., Simmons, K. & Gilbert, D. (2000). Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro dynamic model. Antimicrobial Agents and Chemotherapy 44, Lister, P. D. & Sanders, C. C. (2001). Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 47, Zhanel, G. G., Walters, M., Laing, N. & Hoban, D. J. (2001). In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 47, Lister, P. D. (2002). Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/mic ratios on eradication. Antimicrobial Agents and Chemotherapy 46, MacGowan, A. P., Rogers, C. A., Holt, H. A., Wootton, M. & Bowker, K. E. (2001). Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection. Antimicrobial Agents and Chemotherapy 45, Coyle, E. A., Kaatz, G. W. & Rybak, M. J. (2001). Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 45, Firsov, A. A., Lubenko, I. Y., Portnoy, Y. A., Zinner, S. H. & Vostrov, S. N. (2001). Relationships of the area under the curve/ MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrobial Agents and Chemotherapy 45, Firsov, A. A., Zinner, S. H., Vostrov, S. N., Portnoy, Y. A. & Lubenko, I. Y. (2002). AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. Journal of Antimicrobial Chemotherapy 50, National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA. 18. Wright, D. H., Brown, G. H., Peterson, M. L. & Rotschafer, J. C. (2000). Application of fluoroquinolone pharmacodynamics. Journal of Antimicrobial Chemotherapy 46, Ng, W., Lutsar, I., Wubbel, L., Ghaffar, F., Jafri, H., McCracken, G. H. et al. (1999). Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. Journal of Antimicrobial Chemotherapy 43, Mattoes, H. M., Banevicius, M., Li, D., Turley, C., Xuan, D., Nightingale, C. H. et al. (2001). Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 45, Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B. & Pierce, P. F. (2001). Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrobial Agents and Chemotherapy 45, Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37,
7 Fluoroquinolone exposure in an infection model 23. Bedos, J. P., Azoulay-Dupuis, E., Moine, P., Muffat-Joly, M., Veber, B., Pocidalo, J. J. et al. (1998). Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. Journal of Pharmacology and Experimental Therapeutics 286, MacGowan, A., Rogers, C. & Bowker, K. (2000). The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. Journal of Antimicrobial Chemotherapy 46, Sanchez-Recio, M. M., Colino, C. I. & Sanchez-Navarro, A. (2000). A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. Journal of Antimicrobial Chemotherapy 45,
8
Journal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationAlasdair P. MacGowan,* Chris A. Rogers, H. Alan Holt, and Karen E. Bowker
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2003, p. 1088 1095 Vol. 47, No. 3 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.3.1088 1095.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationAUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
Journal of Antimicrobial Chemotherapy (2002) 50, 533 539 DOI: 10.1093/jac/dkf177 AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin
More informationAlasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
Journal of Antimicrobial Chemotherapy (1999) 43, 345 349 JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationChristine E. Thorburn and David I. Edwards*
Journal of Antimicrobial Chemotherapy (2001) 48, 15 22 JAC The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationDoes the Dose Matter?
SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationWhat Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?
SUPPLEMENT ARTICLE PHARMACOLOGY What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories? Jerome J. Schentag, Kristin K. Gilliland, and Joseph A. Paladino State University of New York at
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationStreptococcus pneumoniae Response to Repeated Moxifloxacin or Levofloxacin Exposure in a Rabbit Tissue Cage Model
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 794 799 Vol. 45, No. 3 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.3.794 799.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationIN VITRO ANTIBACTERIAL EFFECT OF ENROFLOXACIN DETERMINED BY TIME-KILLING CURVES ANALYSIS
Bulgarian Journal of Veterinary Medicine (2010), 13, No 4, 218 226 IN VITRO ANTIBACTERIAL EFFECT OF ENROFLOXACIN DETERMINED BY TIME-KILLING CURVES ANALYSIS Summary A. M. HARITOVA 1 & N. V. RUSSENOVA 2
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationPercent Time Above MIC ( T MIC)
8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3
More informationComparative Study of the Mutant Prevention Concentration of Moxifloxacin, Levofloxacin and Gemifloxacin against Pneumococci.
AAC Accepts, published online ahead of print on 14 December 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01353-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationCollege of Pharmacy, University of Minnesota, Minneapolis, Minnesota, 1 and St. Paul-Ramsey Medical Center, St. Paul, Minnesota 2
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1996, p. 627 632 Vol. 40, No. 3 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Twenty-Four-Hour Area under the Concentration-Time Curve/MIC
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationUse of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections
SUPPLEMENT ARTICLE Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections David S. Burgess College of Pharmacy, University of Texas at Austin,
More informationAdvance Access published September 16, 2004
Advance Access published September 16, 2004 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkh435 JAC Post-antibiotic effect induced by an antibiotic combination: influence of mode, sequence and
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationImpact of Spores on the Comparative Efficacies of Five Antibiotics. Pharmacodynamic Model
AAC Accepts, published online ahead of print on 12 December 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01109-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationparameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an
Overview of Newer Antimicrobial Formulations for Overcoming Pneumococcal Resistance William A Craig, MD The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationInfluence of Combination Therapy on the Fluoroquinolone Mutant Prevention Concentration (MPC) in Pseudomonas aeruginosa.
Influence of Combination Therapy on the Fluoroquinolone Mutant Prevention Concentration (MPC) in Pseudomonas aeruginosa Matthew Mayer Supervisor: Dr. George G. Zhanel A thesis submitted in partial fulfillment
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationTreatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis
Journal of Antimicrobial Chemotherapy (2003) 52, 668 674 DOI: 10.1093/jac/dkg403 Advance Access publication 1 September 2003 Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationPharmacodynamics of fluoroquinolones. A. Dalhoff* Bayer AG, Pharma Research Centre, PO Box , Wuppertal, Germany
Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. B, 51 59 Pharmacodynamics of fluoroquinolones JAC A. Dalhoff* Bayer AG, Pharma Research Centre, PO Box 101709, 42096 Wuppertal, Germany Fluctuating
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationFluoroquinolone Resistance in Streptococcus pneumoniae, Area Under the. Curve: Minimum Inhibitory Concentration Ratio and Resistance Development with
AAC Accepts, published online ahead of print on 1 February 00 Antimicrob. Agents Chemother. doi:10.11/aac.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationPierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015
Antimicrobial susceptibility testing for amoxicillin in pigs: the setting of the PK/PD cutoff value using population kinetic and Monte Carlo Simulation Pierre-Louis Toutain, Ecole Nationale Vétérinaire
More informationORIGINAL ARTICLE /j x. Western Reserve University, Cleveland, OH, USA and 3 Wockhardt Research Centre, Aurangabad, India
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01017.x Activity of the new quinolone WCK 771 against pneumococci P. C. Appelbaum 1, G. A. Pankuch 1, B. Bozdogan 1, G. Lin 1, M. R. Jacobs 2, M. V. Patel 3, S.
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationComparison of Efficacies of Oral Levofloxacin and Oral Ciprofloxacin in a Rabbit Model of a Staphylococcal Abscess
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1999, p. 667 671 Vol. 43, No. 3 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Comparison of Efficacies of Oral
More informationJAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model
Journal of Antimicrobial Chemotherapy (2000) 46, 981 985 JAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model Philippe Cottagnoud a *, Cynthia M. Gerber
More informationReceived 17 December 2003; accepted 22 December 2003
Journal of Antimicrobial Chemotherapy (2004) 53, 609 615 DOI: 10.1093/jac/dkh130 Advance Access publication 3 March 2004 In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines,
More informationA. P. MacGowan*, M. Wootton, A. J. Hedges, K. E. Bowker, H. A. Holt and D. S. Reeves
Journal of Antimicrobial Chemotherapy (996) 8, 9-0 A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative /Mactam, aminoglycoside
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationShape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa
J Antimicrob Chemother 15; 7: 1 doi:1.193/jac/dku37 Advance Access publication November 1 Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationORIGINAL ARTICLE /j x. Institute, São Paulo, Brazil
ORIGINAL ARTICLE 1.1111/j.1469-691.27.1885.x Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationPharmacological indices in antibiotic therapy
Advance Access published November 12, 2003 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkg482 Pharmacological indices in antibiotic therapy Antina Barger, Christine Fuhst and Bernd Wiedemann*
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationCeftaroline versus Ceftriaxone in a Highly Penicillin-Resistant Pneumococcal Pneumonia Rabbit Model Using Simulated Human Dosing
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3557 3563 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01773-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Ceftaroline
More informationThe effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice
International Journal of Infectious Diseases (2006) 10, 401 406 http://intl.elsevierhealth.com/journals/ijid The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis
More informationAdvances in Fluoroquinolones Therapy
Advances in Fluoroquinolones Therapy Fluoroquinolones Synthetic antimicrobial agents with the characteristic 4- quinolone ring structure containing a fluorine moiety at the 6-position. Some members also
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationApplication of Pharmacokinetics/ Pharmacodynamics (PK/PD) in Designing Effective Antibiotic Treatment Regimens
Chapman University Chapman University Digital Commons Pharmacy Faculty Books and Book Chapters School of Pharmacy 4-20-2012 Application of Pharmacokinetics/ Pharmacodynamics (PK/PD) in Designing Effective
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationEfficacy of BB-83698, a Novel Peptide Deformylase Inhibitor, in a Mouse Model of Pneumococcal Pneumonia
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2004, p. 80 85 Vol. 48, No. 1 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.1.80 85.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationSESSION XVI NEW ANTIBIOTICS
SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationReceived 20 August 2003/Returned for modification 12 July 2003/Accepted 15 November 2003
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2004, p. 946 953 Vol. 48, No. 3 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.3.946 953.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationDefining Resistance and Susceptibility: What S, I, and R Mean to You
Defining Resistance and Susceptibility: What S, I, and R Mean to You Michael D. Apley, DVM, PhD, DACVCP Department of Clinical Sciences College of Veterinary Medicine Kansas State University Susceptible
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationBaytril 100 (enrofloxacin) Injectable is FDA-approved for BRD control (metaphylaxis) in high-risk cattle.
Baytril 100 (enrofloxacin) Injectable is FDA-approved for BRD control (metaphylaxis) in high-risk cattle. Whether controlling or treating BRD, it s important to kill bacteria to let the calf s immune system
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationAbstract... i. Committee Membership... iii. Foreword... vii. 1 Scope Definitions... 1
Vol. 28 No. 7 Replaces M37-A2 Vol. 22 No. 7 Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents; Approved Guideline Third Edition
More informationVisit ABLE on the Web at:
This article reprinted from: Lessem, P. B. 2008. The antibiotic resistance phenomenon: Use of minimal inhibitory concentration (MIC) determination for inquiry based experimentation. Pages 357-362, in Tested
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin
More informationThere are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
More informationPharmacodynamic Activities of Ciprofloxacin and Sparfloxacin in a Murine Pneumococcal Pneumonia Model: Relevance for Drug Efficacy
0022-3565/98/2861-0029$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 286, No. 1 Copyright 1998 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationPostgraduate Course ERS Glasgow 2004 Antibiotics and the lung: pharmacokinetics
Antibiotics and the lung: pharmacokinetics Educational aims To explain the importance of pulmonary deposition of antimicrobials. To show that drugs that penetrate well and remain at the pulmonary sites
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationLEVOFLOXACIN RESIDUES IN CHICKEN MEAT AND GIBLETS
Bulgarian Journal of Veterinary Medicine (2013), 16, Suppl. 1, 216 219 LEVOFLOXACIN RESIDUES IN CHICKEN MEAT AND GIBLETS R. KYUCHUKOVA 1, V. URUMOVA 2, M. LYUTSKANOV 2, V. PETROV 2 & A. PAVLOV 1 1 Department
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationFactors affecting plate assay of gentamicin
Journal of Antimicrobial Chemotherapy (1977) 3, 17-23 Factors affecting plate assay of gentamicin II. Media D. C. Shanson* and C. J. Hince Department of Medical Microbiology, The London Hospital Medical
More information